Elanco Animal Health Incorporated (ELAN) — closed signal from September 6, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 5, 2025.
Predicted vs. what happened
What happened
Reached its target in 31 days.
The thesis — published September 6, 2025
Elanco's stock improved after good quarterly results and being added to a major index, which raises visibility and can bring automatic buying from investment funds. Excitement is high, but price swings remain large and buying momentum looks weak. We prefer entries near the lower end of the recent range and would add only if strength clearly returns. Also watch rival vaccine news, which could slow gains. A steady 3 month climb back to a prior stall zone seems reasonable.
Primary drivers
- Quarter results beat expectations, backing the growth story.
- Added to a major index, likely bringing automatic buying from funds.
- Investor mood is positive, even though the price still swings a lot.
- Watch rivals' vaccine updates that could pressure sales and shares.
How it played out
ELAN: target reached in 31 days
Lyra published ELAN at $18.43 on September 6, 2025, with 18% expected growth over a short-term window. The thesis pointed to quarterly results that beat expectations, addition to a major index, positive investor mood, weak buying momentum, large price swings, and rival vaccine updates as a risk.
Inside the window, ELAN reached the $21.75 target in 31 days. It later peaked at $23.70 on November 26, 2025, a 28.6% gain. It ended the window at $21.90. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.